newsfilter
← Latest News
Business Wire·

Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK's MHRA

Humanigen, Inc. (NASDAQ:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, today announced it has submitted all the planned mo